Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002267 · ClinicalTrials.gov registry record · NA
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
A NA study, sponsored by Pharmacia.
- Completed
- Registry status
- NA
- Development phase
- 750
- Enrollment target
NCT00002267 is a NA study that has completed, run by Pharmacia. The registered enrollment target is 750 participants.
The verdict
NCT00002267, a NA study, has completed, sponsored by Pharmacia.
- COMPLETED
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
Study Summary
The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if survival is prolonged in patients who receive rifabutin prophylaxis.
Interventions
- DRUG Rifabutin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002267
The ClinicalTrials.gov registry entry for NCT00002267 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacia, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifabutin is the first listed.
NCT00002267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002267 about?
NCT00002267 is a clinical study titled "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial". The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if s...
What is the current status of trial NCT00002267?
This trial is currently completed. It is a NA study. The enrollment target is 750 participants.
What interventions are being tested in trial NCT00002267?
The interventions under investigation include: Rifabutin (DRUG).
Who is sponsoring clinical trial NCT00002267?
This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.